B6;129S4-Glra2^tm1Clc/J

Stock number: 007065
Product name: Glar2 KO

Description

Pyramidal neurons in homozygous mutants for this knock-out fail to respond to glycine and taurine but mice are otherwise normal.

Detailed description

Mice homozygous for this targeted mutation are viable and fertile and do not display any gross physical or behavioral abnormalities. There is no identifiable phenotype in these mice. Expression is eliminated in the brain as determined by RT-PCR and Northern analyses, and in situ hybridization and immunofluorescence of spinal cord and retina. This strain may be helpful in studies to further delineate the role of this gene.

Development

An FRT-flanked PGK-neomycin drug resistance cassette was targeted to replace a 2.3 kb genomic segment containing exons 6 and 7 in a mouse Glra2-containing BAC. A NotI fragment from the BAC was electroporated into an 129S4/SvJae-derived J1 embryonic stem (ES) cell line. Homologously recombined ES cells were injected into blastocysts to generate chimeric animals. The foundation line was backcrossed to C57BL/6.

Allele

Symbol: Glra2^tm1Clc
Name: targeted mutation 1, Constance L Cepko
MGI accession ID: MGI:3662671
Generation method: Targeted
Attributes: Null/Knockout
Marker symbol: Glra2
Marker name: glycine receptor, alpha 2 subunit
Marker synonyms: GLR; MRXSP; RNNEOGLY
Chromosome: X
Strain of origin: 129S4/SvJae
Molecular note: A vector was designed to replace exons 6 and 7 with an FRT-flanked PGK-neomycin cassette. These exons encode two transmembrane domains and a large portion of its ligand binding domain. Alternative splicing of exon 5 with exon 8 would result in an immediate premature stop codon and should lead to a nonsense-mediated degradation of the mRNA. RT-PCR, Northern blot and in situ hybridization assays were performed to confirm absence of transcript in mutants.